NICE Preventing Type 2 Diabetes (PH35)

People with schizophrenia have an increased risk of cardiovascular mortality.

Some atypical antipsychotics, in particular clozapine, olanzapine and quetiapine, have adverse metabolic effects such as weight gain, dyslipidaemia, and hyperglycaemia which are also risk factors. The MHRA recommends that patients having atypical antipsychotics should have:

•    Identification of modifiable risk factors

•    Monitoring for metabolic effects

•    Management of metabolic side-effects

The MHRA recommends all patients with schizophrenia should have regular physical monitoring and appropriate treatment in line with NICE guideline on Schizophrenia.

For further information:

http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON111764

Photo taken from here. No changes made.